Pilot study of recombinant interferon alpha-2a for treatment of infants with bronchiolitis induced by respiratory syncytial virus

Antimicrob Agents Chemother. 1988 Apr;32(4):589-91. doi: 10.1128/AAC.32.4.589.

Abstract

Eleven children with bronchiolitis induced by respiratory syncytial virus received 10,000 to 70,000 U of recombinant interferon alpha-2a per kg of body weight per day. None developed signs of toxicity, and all but one developed an antiviral state following treatment. Interferon alpha-2a appears to be safe for infants with bronchiolitis. Its efficacy for the treatment of this condition remains to be determined.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies / analysis
  • Biological Assay
  • Bronchiolitis, Viral / microbiology
  • Bronchiolitis, Viral / therapy*
  • Humans
  • Infant
  • Interferon Type I / analysis
  • Interferon Type I / immunology
  • Interferon Type I / therapeutic use*
  • Pilot Projects
  • Respiratory Syncytial Viruses / drug effects
  • Respirovirus Infections / therapy*

Substances

  • Antibodies
  • Interferon Type I